SG/PUT/BRISTOL-MYERS SQUIBB/45/0.1/21.03.25

SG/PUT/BRISTOL-MYERS SQUIBB/45/0.1/21.03.25 Stock

DE000SU7K512

Market Closed - Boerse Frankfurt Warrants 03:37:24 2024-07-16 pm EDT
0.55 ^EUR	-9.84%

Current month	-3.51%
1 month	-3.51%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/PUT/BRISTOL-MYERS SQUIBB/45/0.1/21.03.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained	Jul. 16	MT
Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM	Jul. 15
UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	Jul. 12	MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	Jul. 11	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-16	0.55	-9.84%
24-07-15	0.61	+5.17%
24-07-12	0.58	+1.75%
24-07-11	0.57	+1.79%
24-07-10	0.56	-1.75%

Real-time Boerse Frankfurt Warrants

Last update July 16, 2024 at 03:37 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SU7K51
ISIN	DE000SU7K512
Date issued	2024-01-29
Strike	45 $
Maturity	2025-03-21 (248 Days)
Parity	10 : 1
Emission price	0.33 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.66 €
Lowest since issue	0.16 €
Spread	0.01 €
Spread %	1.82%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company